Chanh Ho Quang, Trieu Huynh Trung, Tam Dong Thi Hoai, Tran Kim Hung, Huynh Ngoc Thien Vuong, Phan Tu Qui, Huyen Vu Ngo Thanh, Alexandra Moncada, Thanh Kieu Nguyen Thi, Duyen Huynh Thi Le, Ngan Nguyen-Lyle, Vuong Nguyen Lam, Lam Phung Khanh, Angela McBride, Bridget Wills, Sophie Yacoub
{"title":"小儿登革热休克综合征中心血管和炎症生物标记物的动力学研究","authors":"Chanh Ho Quang, Trieu Huynh Trung, Tam Dong Thi Hoai, Tran Kim Hung, Huynh Ngoc Thien Vuong, Phan Tu Qui, Huyen Vu Ngo Thanh, Alexandra Moncada, Thanh Kieu Nguyen Thi, Duyen Huynh Thi Le, Ngan Nguyen-Lyle, Vuong Nguyen Lam, Lam Phung Khanh, Angela McBride, Bridget Wills, Sophie Yacoub","doi":"10.1093/oxfimm/iqae005","DOIUrl":null,"url":null,"abstract":"\n \n \n Glycocalyx disruption and hyperinflammatory responses are implicated in the pathogenesis of dengue-associated vascular leak, however little is known about their association with clinical outcomes of patients with dengue shock syndrome (DSS). We investigated the association of vascular and inflammatory biomarkers with clinical outcomes and their correlations with clinical markers of vascular leakage.\n \n \n \n We performed a prospective cohort study in Viet Nam. Children ≥ 5 years of age with a clinical diagnosis of DSS were enrolled into this study. Blood samples were taken daily during ICU stay and 7–10 days after hospital discharge for measurements of plasma levels of Syndecan-1, Hyaluronan, Suppression of tumorigenicity 2 (ST-2), Ferritin, N-terminal pro Brain Natriuretic Peptide (NT-proBNP), and Atrial Natriuretic Peptide (ANP). The primary outcome was recurrent shock.\n \n \n \n 90 DSS patients were enrolled. Recurrent shock occurred in 16 patients. All biomarkers, except NT-proBNP, were elevated at presentation with shock. There were no differences between compensated and decompensated DSS patients. Glycocalyx markers were positively correlated with inflammatory biomarkers, haematocrit, percentage hemoconcentration, and negatively correlated with stroke volume index. While Syndecan-1, Hyaluronan, Ferritin, and ST-2 improved with time, ANP continued to be raised at follow-up. Enrolment Syndecan-1 levels were observed to be associated with developing recurrent shock although the association did not reach the statistical significance at the P < 0.01 (OR = 1.82, 95% CI 1.07–3.35, P = 0.038).\n \n \n \n Cardiovascular and inflammatory biomarkers are elevated in DSS, correlate with clinical vascular leakage parameters and follow different kinetics over time. Syndecan-1 may have potential utility in risk stratifying DSS patients in ICU.\n","PeriodicalId":74384,"journal":{"name":"Oxford open immunology","volume":"29 7","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Kinetics of cardiovascular and inflammatory biomarkers in paediatric dengue shock syndrome\",\"authors\":\"Chanh Ho Quang, Trieu Huynh Trung, Tam Dong Thi Hoai, Tran Kim Hung, Huynh Ngoc Thien Vuong, Phan Tu Qui, Huyen Vu Ngo Thanh, Alexandra Moncada, Thanh Kieu Nguyen Thi, Duyen Huynh Thi Le, Ngan Nguyen-Lyle, Vuong Nguyen Lam, Lam Phung Khanh, Angela McBride, Bridget Wills, Sophie Yacoub\",\"doi\":\"10.1093/oxfimm/iqae005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n \\n \\n Glycocalyx disruption and hyperinflammatory responses are implicated in the pathogenesis of dengue-associated vascular leak, however little is known about their association with clinical outcomes of patients with dengue shock syndrome (DSS). We investigated the association of vascular and inflammatory biomarkers with clinical outcomes and their correlations with clinical markers of vascular leakage.\\n \\n \\n \\n We performed a prospective cohort study in Viet Nam. Children ≥ 5 years of age with a clinical diagnosis of DSS were enrolled into this study. Blood samples were taken daily during ICU stay and 7–10 days after hospital discharge for measurements of plasma levels of Syndecan-1, Hyaluronan, Suppression of tumorigenicity 2 (ST-2), Ferritin, N-terminal pro Brain Natriuretic Peptide (NT-proBNP), and Atrial Natriuretic Peptide (ANP). The primary outcome was recurrent shock.\\n \\n \\n \\n 90 DSS patients were enrolled. Recurrent shock occurred in 16 patients. All biomarkers, except NT-proBNP, were elevated at presentation with shock. There were no differences between compensated and decompensated DSS patients. Glycocalyx markers were positively correlated with inflammatory biomarkers, haematocrit, percentage hemoconcentration, and negatively correlated with stroke volume index. While Syndecan-1, Hyaluronan, Ferritin, and ST-2 improved with time, ANP continued to be raised at follow-up. Enrolment Syndecan-1 levels were observed to be associated with developing recurrent shock although the association did not reach the statistical significance at the P < 0.01 (OR = 1.82, 95% CI 1.07–3.35, P = 0.038).\\n \\n \\n \\n Cardiovascular and inflammatory biomarkers are elevated in DSS, correlate with clinical vascular leakage parameters and follow different kinetics over time. Syndecan-1 may have potential utility in risk stratifying DSS patients in ICU.\\n\",\"PeriodicalId\":74384,\"journal\":{\"name\":\"Oxford open immunology\",\"volume\":\"29 7\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-06-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oxford open immunology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/oxfimm/iqae005\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oxford open immunology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/oxfimm/iqae005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Kinetics of cardiovascular and inflammatory biomarkers in paediatric dengue shock syndrome
Glycocalyx disruption and hyperinflammatory responses are implicated in the pathogenesis of dengue-associated vascular leak, however little is known about their association with clinical outcomes of patients with dengue shock syndrome (DSS). We investigated the association of vascular and inflammatory biomarkers with clinical outcomes and their correlations with clinical markers of vascular leakage.
We performed a prospective cohort study in Viet Nam. Children ≥ 5 years of age with a clinical diagnosis of DSS were enrolled into this study. Blood samples were taken daily during ICU stay and 7–10 days after hospital discharge for measurements of plasma levels of Syndecan-1, Hyaluronan, Suppression of tumorigenicity 2 (ST-2), Ferritin, N-terminal pro Brain Natriuretic Peptide (NT-proBNP), and Atrial Natriuretic Peptide (ANP). The primary outcome was recurrent shock.
90 DSS patients were enrolled. Recurrent shock occurred in 16 patients. All biomarkers, except NT-proBNP, were elevated at presentation with shock. There were no differences between compensated and decompensated DSS patients. Glycocalyx markers were positively correlated with inflammatory biomarkers, haematocrit, percentage hemoconcentration, and negatively correlated with stroke volume index. While Syndecan-1, Hyaluronan, Ferritin, and ST-2 improved with time, ANP continued to be raised at follow-up. Enrolment Syndecan-1 levels were observed to be associated with developing recurrent shock although the association did not reach the statistical significance at the P < 0.01 (OR = 1.82, 95% CI 1.07–3.35, P = 0.038).
Cardiovascular and inflammatory biomarkers are elevated in DSS, correlate with clinical vascular leakage parameters and follow different kinetics over time. Syndecan-1 may have potential utility in risk stratifying DSS patients in ICU.